共 50 条
- [31] A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody-drug conjugate, in patients with advanced or metastatic cancerINVESTIGATIONAL NEW DRUGS, 2021, 39 (06) : 1613 - 1623Kollmannsberger, ChristianBritten, Carolyn D.Olszanski, Anthony J.Walker, Joan AndrewsZang, WeiWillard, Melinda D.Radtke, David B.Farrington, Daphne L.Bell-McGuinn, Katherine M.Patnaik, Amita
- [32] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsNature Communications, 15Gail D. LewisGuangmin LiJun GuoShang-Fan YuCarter T. FieldsGenee LeeDonglu ZhangPeter S. DragovichThomas PillowBinQing WeiJack SadowskyDouglas LeipoldTim WilsonAmrita KamathMichael MamounasM. Violet LeeOla SaadVoleak ChoeurngAlexander UngewickellSharareh MonemiLisa CrockerKevin KalinskyShanu ModiKyung Hae JungErika HamiltonPatricia LoRussoIan KropMelissa M. SchuttenRenee CommerfordMark X. SliwkowskiEunpi Cho
- [33] The HER2-directed antibody-drug conjugate DHES0815A in advanced and/or metastatic breast cancer: preclinical characterization and phase 1 trial resultsNATURE COMMUNICATIONS, 2024, 15 (01)Lewis, Gail D.Li, GuangminGuo, JunYu, Shang-FanFields, Carter T.Lee, GeneeZhang, DongluDragovich, Peter S.Pillow, ThomasWei, BinqingSadowsky, JackLeipold, DouglasWilson, TimKamath, AmritaMamounas, MichaelLee, M. VioletSaad, OlaChoeurng, VoleakUngewickell, AlexanderMonemi, ShararehCrocker, LisaKalinsky, KevinModi, ShanuJung, Kyung HaeHamilton, ErikaLoRusso, PatriciaKrop, IanSchutten, Melissa M.Commerford, ReneeSliwkowski, Mark X.Cho, Eunpi
- [34] TARGETING CD70 IN NON-HODGKIN LYMPHOMA AND RENAL CELL CARCINOMA: A PHASE 1 STUDY OF THE ANTIBODY-DRUG CONJUGATE SGN-75ANNALS OF ONCOLOGY, 2010, 21 : 174 - 174Ansell, S. M.Thompson, J. A.Infante, J.Heath, E. I.Whiting, N. C.Zhao, B.Forero-Torres, A.
- [35] Phase I Study of Trastuzumab-DM1, an HER2 Antibody-Drug Conjugate, Given Every 3 Weeks to Patients With HER2-Positive Metastatic Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (16) : 2698 - 2704Krop, Ian E.Beeram, MuralidharModi, ShanuJones, Suzanne F.Holden, Scott N.Yu, WeiGirish, SandhyaTibbitts, JayYi, Joo-HeeSliwkowski, Mark X.Jacobson, FredLutzker, Stuart G.Burris, Howard A.
- [36] Results from the phase 1/2 study of patritumab deruxtecan, a HER3-directed antibody-drug conjugate (ADC), in patients with HER3-expressing metastatic breast cancer (MBC).JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)Krop, Ian E.Masuda, NorikazuMukohara, ToruTakahashi, ShunjiNakayama, TakahiroInoue, KenichiIwata, HirojiToyama, TatsuyaYamamoto, YutakaHansra, Damien MikaelTakahashi, MasatoOsaki, AkihikoKoyama, KumikoInoue, TatsuyaYonekura, TakatoshiMostillo, JosephOhwada, ShoichiTanaka, YoshimiSternberg, David W.Yonemori, Kan
- [37] Phase 1a study of ESG401, a Trop2 antibody-drug conjugate, in patients with locally advanced/metastatic solid tumorsCELL REPORTS MEDICINE, 2024, 5 (09)Wang, JianiTong, ZhongshengTan, YinuoShi, YehuiWu, YunZhou, QingXing, XiaoyanChen, XiaomeiQiu, FumingMa, Fei
- [38] Development of a CUB domain-containing protein 1 (CDCP1)-targeting antibody-drug conjugate for triple-negative and metastatic breast cancerJOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)Gough, MadelineKwah, KaydenHe, YaowuSnell, Cameron EdwardHooper, John D.Kryza, Thomas
- [39] A phase I study of a first-in-class HER2 antibody-drug conjugate in patients with HER2-overexpressing metastatic breast cancer.BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S104 - S104Burris, H. A.Krop, I. E.Modi, S.Rodon, J.Lutzker, S. G.Holden, S. N.Bhattacharya, S.Sliwkowski, M. X.Beeram, M.
- [40] Phase Ib/II study of antibody-drug conjugate, sacituzumab govitecan, in combination with the PARP inhibitor, talazoparib, in metastatic triple-negative breast cancerANNALS OF ONCOLOGY, 2020, 31 : S394 - S394Bardia, A.Spring, L. M.Juric, D.Partridge, A.Ligibel, J.Kuter, I.Peppercorn, J.Parsons, H.Ryan, P.Chawla, D.Attaya, V.Fitzgerald, D. M.Viscosi, E.Lormill, B.Shellock, M.Moy, B.Tolaney, S. M.Ellisen, L. W.